CLINICAL EFFICACY OF ALBUMIN-BOUND PACLITAXEL AND PLATINUM CHEMOTHERAPY IN ADVANCED OR RECURRENT GYNECOLOGICAL TUMORS IN FEMALE ATHLETES

Abstract

Objective: To assess the therapeutic impact and safety of albumin-bound paclitaxel combined with platinum-based chemotherapy in treating advanced or recurrent gynecological malignancies, with a focus on female athletes. Methods: This study, conducted from May 2018 to May 2020, involved 76 female athletes diagnosed with advanced or recurrent gynecological tumors at our institution. Participants were randomly allocated into two groups: one receiving albumin-bound paclitaxel and platinum-based chemotherapy, and the other receiving only albumin-bound paclitaxel. We compared the clinical outcomes and side effects of the two treatment regimens. Results: The group treated with the combination of albumin-bound paclitaxel and platinum showed a significantly higher overall response rate of 79.85% compared to 52.63% in the group treated with albumin-bound paclitaxel alone (P<0.05). The incidence of adverse drug reactions (ADRs) did not differ significantly between the two groups (P>0.05), indicating a comparable safety profile. Conclusion: The combination of albumin-bound paclitaxel and platinum-based chemotherapy exhibits superior efficacy in the treatment of advanced or recurrent gynecological tumors among female athletes, without increasing the risk of ADRs. This regimen offers a promising therapeutic option and merits broader clinical application.